About Us

BioLife is a cross-border access, commercialization, and strategic collaboration platform focused on two-way healthcare market entry between the U.S. and China.

We focus on cross-border opportunities that require real execution, rather than simply building connections. Our role is to help qualified technologies, products, and partnership resources move through market entry, supply chain coordination, channel development, and commercialization.

BioLife’s core value does not lie in any single product, but in our ability to integrate strong technologies, products, manufacturing resources, distribution channels, institutional relationships, and partners to help projects build clearer and more executable growth pathways.

Who We Work With

Innovative technology and product companies

Manufacturers and supply chain partners

Brands and channel partners

Clinics, institutions, and clinical partners

Strategic partners and investment-aligned collaborators

Our Journey & Key Milestones

BioLife’s development has been built on years of international healthcare collaboration, cross-border business development, and platform capability building. The following milestones reflect our long-term development across medical services, supply chain, product commercialization, and cross-border collaboration.

2015

Advanced European healthcare resource integration efforts

BioLife signed an acquisition agreement with the UK-based 352 Hospital Group, further advancing its international healthcare resource integration and platform development efforts.

2013

Entered the international healthcare platform operating stage

BioLife acquired and operated the biggest biological group---Swiss Biological Medicine Group and managed its affiliated Paracelsus Klinik hospital. Founded in 1958, the hospital served patients from 81 countries worldwide.

2021

Expanded U.S. medical device and supply chain collaboration

BioLife formed Toptolife LLC in the United States with CommonSpirit, the largest nonprofit hospital group in the U.S., focusing on medical device and healthcare supply chain collaboration. The business launched a portfolio of more than 10,000 medical consumable SKUs and served over 2,000 hospitals and clinics.

2018

Launched a U.S.-China joint venture in healthcare services and supply chain collaboration

BioLife formed BioLife Dignity Health International Ltd. with Dignity Health, then the fourth-largest hospital group in the United States, focusing on cross-border healthcare service collaboration and medical supply chain coordination between the U.S. and China.

2025

Introduced a rapid testing system for U.S. clinic settings

BioLife launched a rapid testing system for the U.S. clinic market, further expanding its capabilities in diagnostic products, clinical workflow support, and clinic-based commercialization.

2024

Expanded into consumer health and cross-border brand operations

BioLife launched cross-border operations for four supplement brand lines, including ARTHUR ANDREW, further extending into health management and consumer health.

2026

Advanced imaging and AI-aided systems entered the U.S. market pipeline

In March 2026, BioLife began introducing the Photoacoustic Imaging System, Active Pathology Imaging System, and Innovision Eagle-Eye AI-Aided System into the U.S. market.

Execution-Oriented — We focus on collaboration pathways that can be realistically executed and implemented.

Selective Partnership — We prioritize quality, long-term value, and strategic fit.

Long-Term Alignment — We aim to build sustainable commercial and strategic outcomes with our partners.

To become a trusted cross-border access and commercialization platform for healthcare opportunities between the U.S. and China.

To help healthcare technologies, products, and partnership resources move across market entry barriers between the U.S. and China and achieve more practical, sustainable commercialization.